A highly selective, orally active inhibitor of Janus kinase 2, CEP-33779, ablates disease in two mouse models of rheumatoid arthritis.

Stump, Kristine L; Lu, Lily D; Dobrzanski, Pawel; Serdikoff, Cynthia; Gingrich, Diane E; Dugan, Ben J; Angeles, Thelma S; Albom, Mark S; Ator, Mark A; Dorsey, Bruce D; Ruggeri, Bruce A; Seavey, Matthew M.
Arthritis Res Ther; 13(2): R68, 2011 Apr 21.
Artigo em Inglês | MEDLINE | ID: mdl-21510883